During the 2014–2015 West African Ebola epidemic, many argued that randomized clinical trials—our most reliable way of evaluating new treatments and vaccines—were neither ethical nor feasible in an environment with limited health infrastructure, where severe disease was causing many fatalities. Susan Ellenberg, PhD, and colleagues look at the trials that did occur and comment on strategies for the future.